Loading…
Loading…
The Invesco International Dividend Achievers Exchange Traded Fund (Fund) aims to mirror the performance of the NASDAQ International Dividend Achievers Index (Index). Typically, the Fund commits at least 90% of its total capital to dividend-paying common stocks and other types of securities that constitute this Index. The Index itself is designed to identify a worldwide selection of American Depository Receipts, Global Depositary Receipts, and non-U.S. common or ordinary shares that have earned the designation of International Dividend Achievers. To qualify, these companies must have…
Is PID's expense ratio expensive, average, or a steal for its category?
Pro reveals the verdict on a 5-tier spectrum calibrated against ICI 2025 industry averages, with strategy-aware bands so the comparison is meaningful.
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda presents Phase 2/3 study results for TAK-881 in primary immunodeficiency (PID), showing comparability to HYQVIA with 50% less IG volume.
The Invesco International Dividend Achievers ETF retains a Sell rating due to persistent underperformance and elevated risk metrics versus international benchmarks. PID's strategy of targeting dividend growers lacks a quality screen, resulting in weak dividend growth and total return relative to the benchmark ACWX. The fund's high expense ratio (0.53%) and heavy Canadian concentration undermine its appeal for international diversification.
Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, today announced the MIUD
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda announced that TAK-881-3001, a pivotal Phase 2/3 clinical trial in Primary Immunodeficiency Disease (PID) patients, met its primary endpoint.